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Sensitization to the Yeast Malassezia Sympodialis
Is Specific for Extrinsic and Intrinsic Atopic Eczema
Barbra Fischer Casagrande1, Sabine Flu¨ckiger2, Maria T. Linder3, Catharina Johansson3, Annika Scheynius3,
Reto Crameri2 and Peter Schmid-Grendelmeier1
The opportunistic yeast Malassezia sympodialis belongs to the normal cutaneous flora but can also cause IgE-
mediated sensitization in patients suffering from atopic eczema (AE). We investigated 706 individuals by
ImmunoCAPm70 and skin-prick tests with a crude M. sympodialis extract. In AE patients, we further performed
skin prick tests, atopy patch tests, ELISA, and peripheral blood mononuclear cells proliferation assays with
recombinant M. sympodialis allergens (rMala s 1 and 5–9). In 52/97 patients with AE-specific IgE against M.
sympodialis was detectable. Almost no reactivity to M. sympodialis was seen in patients suffering from other
allergic diseases (4/571) and no reactivity at all was seen in healthy controls (0/38). Skin tests showed variable
recognition patterns against the different molecular structures with a predominant sensitization to rMala s 1, 5,
6, and 9, confirmed also by specific serum IgE to these allergens. Interestingly, IgE- and T-cell-mediated reactivity
against M. sympodialis was also found in patients with the intrinsic form of AE. Thus, sensitization to
M. sympodialis is specific for AE patients and occurs in both the extrinsic and intrinsic variant of eczema.
Recombinant yeast allergens represent a useful tool to study molecular structures and differential sensitization
patterns in the pathogenesis of AE.
Journal of Investigative Dermatology (2006) 126, 2414–2421. doi:10.1038/sj.jid.5700431; published online 15 June 2006
INTRODUCTION
Atopic eczema (AE) is a chronically relapsing inflammatory
skin disease, where the pathogenesis is not yet fully under-
stood (Leung, 2000). However, a combination of genetic
background, deregulation of the immune system, a defective
skin barrier, and environmental factors contribute to the
development of AE (Leung and Bieber, 2003). Approximately
80% of the adult AE patients show immediate-type skin
reactions to environmental allergens together with elevated
serum IgE levels. However, approximately 20% of patients
with clinical signs of AE have low serum IgE levels and lack
detectable specific serum IgE and positive skin prick test (SPT)
reactions to such allergens. This subgroup is also defined as
intrinsic, non-allergic AE or more recently non-atopic type of
eczema (Oppel et al., 2000; Schmid-Grendelmeier et al.,
2001; Johansson et al., 2004b). As the serum level of IgE to
aero- and food allergens in the extrinsic type can correlate
with the severity of AE (Scalabrin et al., 1999) and increased
number of IgE receptors are found on cutaneous antigen-
presenting cells (Bruynzeel-Koomen et al., 1986; Bieber
et al., 1992), it can be postulated that allergens can be
involved in the onset and/or maintenance of the disease.
Microorganisms have also been particularly emphasized as
pathogenetic factors; in particular, Staphylococcus aureus and
the skin colonizing opportunistic yeast Malassezia, earlier
denoted as Pityrosporum (Jensen-Jarolim et al., 1992; Scalabrin
et al., 1999; Scheynius et al., 2002). Recently, such micro-
organisms have been postulated to be pathogenetically relevant
also in a proportion of patients with the intrinsic form of AE
(Johansson et al., 2003; Novak et al., 2003). M. sympodialis
has been reported as the most frequent species in both AE
patients and healthy individuals (Sandstrom Falk et al., 2005).
In previous studies, it was demonstrated that around
30–80% of patients with AE have positive SPT, positive atopy
patch test (APT) reactions, and/or IgE antibodies against
extract of Malassezia (Rokugo et al., 1990; Nissen et al.,
1998; Mayser and Gross, 2000; Tengvall Linder et al., 2000;
Zargari et al., 2001; Scheynius et al., 2002; Johansson et al.,
2003; Johansson et al., 2004a). Proliferative responses of
peripheral blood mononuclear cells (PBMCs) after stimula-
tion with M. sympodialis extract are significantly higher in
AE patients with Malassezia-specific serum IgE than in AE
patients lacking Malassezia-specific serum IgE and in non-
atopic healthy controls (Tengvall Linder et al., 1998;
Johansson et al., 2002; Scheynius et al., 2002). All these
data indicate that the sensitization to M. sympodialis is a
phenomenon specific for AE. However, studies in larger
populations addressing this question are still lacking, namely
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also in intrinsic AE. Thus, we investigated the differential
reactivity to M. sympodialis in various conditions, including
various immediate-type allergic diseases, urticaria, and
allergic contact dermatitis (ACD) (n¼ 571) using SPT with
natural extract and ImmunoCAPm70. Furthermore, we
performed in the patient group with AE SPT, APT, ELISA,
and a PBMC proliferation assay with the six recombinant
M. sympodialis allergens rMala s 1 and rMala s 5–9 to further
characterize particular allergens involved in both extrinsic
and intrinsic AE.
RESULTS
Response to M. sympodialis extract
From all the 706 tested individuals (97 AE patients, 571
patients with other diseases, and 38 healthy controls), only
the patient group with AE showed a high percentage of
sensitization to natural M. sympodialis extract. In 52 of
97 patients (54%) with AE specific IgE reactivity against
M. sympodialis extract was detected either serologically
with the ImmunoCAPm70 system (median 18 kU/l, range
0.39–79.6 kU/l) or in SPT. From the 571 patients with other
allergic diseases, only four patients (two with rhinoconjunc-
tivitis, two with asthma bronchiale) showed a weak IgE
reaction to M. sympodialis extract either in ImmunoCAPm70
or in SPT (Table 1). The clinical investigation and the
retrospective evaluation of the clinical history showed that
two of these patients presented marginal signs for an AE and
that the other two were previously afflicted with an AE. All
healthy controls showed no IgE-mediated reaction to the M.
sympodialis extract (Table 1). In the APT with M. sympodialis
extract, 34 of the 69 tested AE patients (49%) showed a
positive reaction (Table 3). Even 12 of the 16 tested patients
(75%) reacted positive in the PBMC proliferation assay to
M. sympodialis extract (Table 3).
In vivo response to rMala s allergens
Figure 1 shows the differential SPT and APT reactivity of the
AE patients against the different recombinant M. sympodialis
allergens with a predominance of sensitization to rMala s 1,
rMala s 5, rMala s 6, and rMala s 9 in both types of skin tests.
Overall, 41 of 97 tested patients (42%) reacted to at least one
rMala s protein (any rMala s) in the SPT, whereas 33 of 69
tested patients (48%) reacted to at least one rMala s protein
(any rMala s) in the APT (Table 3). These results were just a
little bit below the positive reactions detected by the natural
extract (46 and 49%, respectively).
In vitro response to rMala s allergens
So far, the biological relevance of ELISA measurements of IgE
reactivity with recombinant M. sympodialis allergens has not
been determined. To assess the approximate cutoff values
of the optical density (OD) for a given allergen in terms
of biological activity, the quantitative OD measurements
have to be correlated to the in vivo results. The patients were
divided into four groups (SPTþAPTþ , SPTþAPT,
Table 1. Characteristics of study population and sensitization to M. sympodialis extract
Totally tested
Allergic manifestations
other than stated Gender (M/F)1
Median age years
(range)
Pos. ‘‘m70’’2
(30.35 kU/l)
Pos. SPT to nat.
extract
Asthma 83 69 rhinitis/conjunctivitis 0.8 23 (5–72) 1 1
Rhinitis/conjunctivitis 378 55 asthma, 20 food allergy 0.9 27 (6–63) 0 2
AE 97 — 0.8 32 (17–56) 51 45
Urticaria 31 2 food allergy 0.2 42 (15–48) 0 0
Food allergy 24 — 0.4 26 (11–52) 0 0
Insect sting allergy 42 — 0.5 35 (9–64) 0 0
ACD 13 — 0.6 33 (17–63) 0 0
Healthy controls 38 — 0.4 29 (15–61) 0 0
Total 706 — 0.6 31 (5–72) 52 48
AE, atopic eczema; ACD, allergic contact dermatitis; F, female; ‘‘m70’’, ImmunoCAPm70; M, male; SPT, skin prick test.
1Ratios refer to male divided by female.
2‘‘m70’’ is the commercially available ImmunoCap test for M. sympodialis ATCC yeast strain 42132.
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Figure 1. SPT and APT reactions with rMala s allergens in patients with AE.
In this figure, we show the percentage of patients who reacted positive in the
SPT (performed in all patients, n¼ 97) or the APT (performed in n¼69
patients) to rMala s allergens. SPT was considered as positive by a wheal
diameter ofX3 mm surrounded by erythema. APT was considered as positive
when there was at least an erythema and infiltration (þ ) after 48 and/or
72 hours.
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SPTAPTþ , SPTAPT) based on the in vivo tests to the
natural extract. Because the mean OD of the SPTþ /APTþ
tested patients was 0.9 and the mean OD of the SPT/APT
tested patients was 0.09, we defined 0.3 as the limit for
positive ELISA reactions for rMala s (Figure S1). Overall, 53%
(51/97) reacted to one of the recombinant M. sympodialis
allergens with a predominance of sensitization to rMala s 1,
rMala s 5, rMala s 6, and rMala s 9 (Table 3). Almost no
reaction to rMala s 7 and rMala s 8 was observed (Figure 2).
In the patient group, where we performed PBMC proliferation
assays (n¼16), we could induce a positive proliferation with
all rMala s allergens, except for rMala s 5. A predominance
of T-cell sensitization was seen to rMala s 1, rMala s 6, and
rMala s 9. In all individuals of the negative control group
(n¼3), the PBMC proliferation assay was negative (Table 3).
Intrinsic AE patient group
From the 97 patients with AE, 41 had a head-and-neck type
whereas 56 had a more generalized form. Eighty-three were
of the extrinsic type (36 with head-and-neck type) and 14
of the intrinsic type (five with head-and-neck type) (Table 2).
All intrinsic AE patients had a total IgE level below 350 kU/l.
Interestingly, also the patient group with the so-called
intrinsic type of AE (because of the absence of specific IgE
to the common aero- and food allergens) showed in vivo skin
test reactivity to M. sympodialis extract (SPT 36%, APT 38%)
and also to the different rMala s proteins except for rMala s 7
(Table 4). Furthermore, 7/14 (50%) showed positive Immu-
noCAPm70 reactions, respective positive ELISA reactions
to any rMala s proteins. In the PBMC proliferation assay, 5/8
(63%) reacted to the natural M. sympodialis extract. Also the
rMala s allergens could induce a positive proliferation assay,
except rMala s 5 and rMala s 7 (Table 4).
DISCUSSION
Our study fully confirms in a large patient number that
sensitization to M. sympodialis is found exclusively in
patients with AE, but not in other hypersensitive diseases
such as patients with inhalant, food or insect venom
allergies, urticaria, or ACD. Thus, sensitization against
M. sympodialis can be regarded as specific or almost
pathognomonic for AE, both in generalized and in the
head-and-neck type. According to the literature, where
Malassezia-specific serum IgE was detected with a frequency
of 32–68% and positive SPT to Malassezia was found in
approximately 30–80% of AE patients (Nordvall et al., 1992;
Scalabrin et al., 1999; Tengvall Linder et al., 2000; Zargari
et al., 2001; Johansson et al., 2002; Scheynius et al., 2002),
we can confirm this type I sensitization in 53% (51/97) of
the AE patients tested by the ImmunoCAPm70-system and
in 46% (45/97) tested by SPT (Table 1). Also in the APT, 49%
(34/69) of the patients reacted positively to natural extract
(Table 3), this was in accordance with previous studies,
where positive APT to Malassezia was found in 41–64% of
the AE patients (Rokugo et al., 1990; Tengvall Linder et al.,
2000; Johansson et al., 2003).
It is not yet fully understood why sensitization against M.
sympodialis occurs only in the patient group with AE, but
not in patients with exclusively inhalant symptoms such
as rhinoconjunctivitis and/or asthma. A possible cause is the
high, long-standing cutaneous colonization with Malassezia.
Antimicrobial peptides known as cathelicidins (LL-37) and
beta-defensins (HBD-2) are deficient in skin lesions from
patients with AE (Ong et al., 2002), which might also
contribute to a higher colonization with Malassezia in this
patient group. Furthermore, the selective sensitization in AE
patients might be favored by the disrupted skin barrier in
AE. Whole yeast cells and allergenic components of the
yeast are likely to pass the skin barrier and come in contact
with professional antigen-presenting cells, such as Langer-
hans cells in the epidermis (Buentke et al., 2000, 2001).
Antigen-presenting cells in the skin of AE patients also have
an increased ability to react to those allergens (Gabrielsson
et al., 2004).
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Figure 2. IgE binding against the various r allergens determined by ELISA in
all patients with AE (n¼97). In this figure, we show only reactions with an
OD 40.3. The line shows the median, the body of the boxes show the
25–75th percentile, and the whiskers show the limit of the 90th, respective the
10th percentile. All observations 490th oro10th percentile are illustrated as
dots.
Table 2. Characteristics of the AE patients
Extrinsic AE
(n=83)
Intrinsic AE
(n=14)1
Median age in years (range) 32 (17–56) 29 (19–53)
Gender M/F 35/48 7/7
SCORAD median (range) 31 (7–76.5) 27 (8.3–79.5)
Total IgE median (kU/l) (range) 2,086 (55–16,400) 194 (18–349)
Inhalation allergies2 37 (45%) 0 (0%)
Head–neck type 36 (43%) 5 (36%)
Sx1 (0.35 kU/l) 81 (99%) 0 (0%)
Fx5 (0.35 kU/l) 18 (23%) 0 (0%)
1Intr. AE=absence of respiratory allergy, negative Sx1 and Fx5, total IgE
o350 kU/l; F, female; Fx5, screening for food-allergies; M, male; Sx1,
screening for respiratory allergies.
2Inhalation allergies=either rhinoconjunctivitis or allergic asthma and pos.
Sx1.
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Furthermore, skin-homing activated T-cells bearing the
cutaneous lymphocytic antigen show increased reactivity in
AE and may contribute to the formation of specific IgE (Akdis
et al., 1997). All these observations support the hypothesis
that penetration of M. sympodialis in AE is possible and can
induce an allergic reaction with a consequent production of
specific IgE via B-cell stimulation in patients with AE.
Interestingly, also in the intrinsic type of AE, we found a
high IgE- and T-cell-mediated sensitization to M. sympodialis
(Table 4). These patients have neither associated respiratory
Table 3. Reactivity to the M. sympodialis extract and different recombinant M. sympodialis allergens in SPT, APT,
and ELISA, and comparision between the reactions to recombinant allergens in various analysis techniques divided
for ImmunoCAPm70 positive and negative results
Natural extract rMala s 1 rMala s 5 rMala s 6 rMala s 7 rMala s 8 rMala s 9 Any rMala1
ImmunoCAPm70 n % n % n % n % n % n % n % n %
SPT (n=97) CAP pos. (n=51) 44 86 19 37 22 43 19 37 3 6 8 16 23 45 39 76
CAP neg. (n=46) 1 2 0 0 1 2 1 2 0 0 0 0 0 0 2 4
Total (n=97) 45 46 19 20 23 24 20 21 3 3 8 8 23 24 41 42
APT (n=69) CAP pos. (n=42) 31 74 14 33 15 36 12 29 2 5 8 19 16 38 33 79
CAP neg. (n=27) 3 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total (n=69) 34 49 14 20 15 22 12 17 2 3 8 12 16 23 33 48
ELISA2 (n=97) CAP pos. (n=51) NA NA 20 39 24 47 28 55 5 10 16 31 31 61 45 88
CAP neg. (n=46) NA NA 0 0 2 4 3 7 1 2 1 2 0 0 6 13
Total (n=97) NA NA 20 21 26 27 31 32 6 6 17 18 31 32 51 53
PBMC3 CAP pos. (n=13) 12 92 6 46 0 0 5 38 1 8 4 31 7 54 11 85
proliferation CAP neg. (n=3) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(n=16) Total (n=16) 12 75 6 38 0 0 5 31 1 6 4 25 7 44 11 69
ATP, atopy patch test; PBMC, peripheral blood mononuclear cells; SPT, skin prick test.
1Any rMala=accumulated results with any recombinant M. sympodialis allergen (rMala s1, rMala s 5–9).
2Positive reaction in the ELISA were defined as an OD 40.3.
3Positive reaction in the PBMC assay were defined as stimulation index 42.5 (results obtained with an allergen concentration of 1 mg/ml after 6 days of cell
culture are shown).
Table 4. Reactivity against the M. sympodialis extract and various recombinant allergens in patients with intrinsic
AE
SPT pos.
(%), n=14
APT pos.
(%), n=13
ELISA pos1.
(median OD, range3), n=14
PBMC proliferation pos2.
(median SI, range3), n=13
M. sympodialis extract 5 (36%) 5 (38%) 74 5 (5.8, 3.1–8.9)
rMala s 1 3 (21%) 2 (15%) 2 (1.13, 1.04–1.21) 4 (3.3, 2.8–3.7)
rMala s 5 2 (14%) 1 (8%) 3 (0.98, 0.87–1.10) 0
rMala s 6 3 (21%) 0 4 (2.74, 2.03–3.71) 2 (5.3, 4.2–6.4)
rMala s 7 0 0 1 (0.37) 0
rMala s 8 3 (21%) 3 (23%) 3 (0.68, 0.41–0.92) 2 (4.5, 3.2–5.8)
rMala s 9 4 (29%) 2 (15%) 5 (1.62, 0.32–4.49) 4 (4.5, 2.9–6.3)
AE, atopic eczema; APT, atopy patch test; PBMC, peripheral blood mononuclear cells; OD, optical density; SPT, skin prick test.
1Positive reaction in the ELISA were defined as an OD 40.3.
2Positive reaction in the PBMC assay were defined as stimulation index 42.5 (results obtained with an allergen concentration of 1 mg/ml after 6 days of cell
culture are shown).
3Median and range is given for positive only.
4IgE analysis for the M. sympodialis extract was carried out with ImmunoCAP (kU/1).
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or food allergies nor detectable IgE-mediated sensitization to
common inhalant or food allergens. However, they also show
a disrupted skin barrier and T cells from those patients
equally respond to superantigen, staphylococcal enterotoxin
B, and produce similar cytokines (Akdis et al., 1997; Novak
and Bieber, 2003). One could speculate that this patient
group – so far defined by the absence of sensitization to
standard aero-/food allergens – is in fact a group of patients
that nevertheless is at risk to get similarly sensitized to other
agents with primary cutaneous exposure such as skin
colonizing microbes as Staphylococci or Malassezia. As
already described elsewhere, microbes such as M. sympo-
dialis might indeed play a role as trigger factors also in
intrinsic AE (Johansson et al., 2003; Novak et al., 2003). The
term intrinsic AE is therefore misleading to a certain extent
(Johansson et al., 2004b). Thus, our results also call into
question the relevance of IgE in the pathogenesis of AE.
Furthermore, we could show a very clear concordance on
the one hand in vivo between SPT and APT (Figure 1), and on
the other hand between the in vivo and in vitro findings
(Table 3). Hence, 86% of the 51 ImmunoCAPm70-positive
tested patients reacted positively in the SPT to natural extract,
and 74% in the APT. This is most probably owing to the fact
that the same allergen extract was used in all in vivo and in
vitro tests (ATCC yeast strain no. 42132).
Malassezia extracts contain a wide range of IgE-binding
components (Zargari et al., 1994; Lintu et al., 1997), but
variations in allergenic contents, difficulties in standardiza-
tion of the extract (Zargari et al., 1995) as well as large batch
to batch variation (Vailes et al., 2001; Zargari et al., 2001)
may be solved by the use of highly pure recombinant
proteins. By investigating in this study six of the known
recombinant M. sympodialis allergens (rMala s 1 and rMala s
5–9) (Schmidt et al., 1997; Lindborg et al., 1999; Rasool et al.,
2000; Andersson et al., 2004), we found a strong correlation
between positive SPT and APT to each recombinant allergen
with a predominance of sensitization to rMala s 1, rMala s 5,
rMala s 6, and rMala s 9 (Figure 1, Table 3). There was a
significant reduced reaction to rMala s 7 in both in vivo tests
(ATP and SPT), also detectable in the ELISA (Figure 2) and in
the PBMC proliferation assay (Table 3).
Of the recombinant M. sympodialis allergens used, only
rMala s 5 and rMala s 6 show sequence similarity to other
proteins; the others, rMala s 1, rMala s 7 to rMala s 9, are
unique structures (Table S1). Hence owing to structural
relationship of fungal manganese superoxide dismutase
(rMala s11) with the human form of this enzyme, IgE- and
T-cell-mediated autoreactivity can result in AE patients
(Schmid-Grendelmeier et al., 2005). Thus, high crossre-
activity between rMala s 6 and human cyclophilin, a protein
found in many organisms and proteins of human (Fluckiger
et al., 2002) and showing the highest sensitization rate in our
study (Table 3, Figure 2), might also induce similar
autoreactivity phenomens in AE.
In conclusion we could demonstrate in a large study
population, that sensitization to M. sympodialis is highly
specific for patients with AE and does not occur in patients
with only inhalant allergies, urticaria, or ACD. Regarding the
high frequency of sensitization to M. sympodialis, one could
argue that these potential microbial allergens should be
added in the diagnostic workup of AE patients, namely also
in the intrinsic type of AE. This might be also relevant for
therapeutic purposes, as various studies have reported
beneficial effects of anti-fungals in some AE patients (Back
et al., 1995; Back and Bartosik, 2001; Lintu et al., 2001;
Ikezawa et al., 2004; Svejgaard et al., 2004). Diagnosis with
recombinant yeast allergens proved as a highly useful tool to
further characterize the allergens involved, and to determine
their clinical relevance in AE.
MATERIALS AND METHODS
Patient selection
Totally, 668 individuals with different allergic diseases (AE, allergic
asthma, rhinitis and/or conjunctivitis, urticaria, food allergy, insect
sting allergy, and ACD), and 38 healthy controls were investigated
(Table 1). Diagnosis of AE was made according to the criteria
of Hanifin and Rajka (Hanifin, 1980). Disease activity for AE was
estimated using SCORAD (severity scoring of atopic dermatitis)
(Consensus Report, 1993). Furthermore, we divided the patients with
AE in the clinical subtype of generalized or head-and-neck type of
AE and also extrinsic and intrinsic type (Table 2) (Wu¨thrich, 1989;
Johansson et al., 2001). The group of intrinsic AE was defined by the
absence of other atopic diseases such as allergic rhinoconjunctivitis
or allergic bronchial asthma and a low or moderate total IgE level
(o350 kU/l) in combination with negative in vitro IgE screening
for aeroallergens and food allergens (e.g., sx1 and fx5, Pharmacia
ImmunoCAP System, Pharmacia Diagnostics AB, Sweden). Patients
with allergic rhinitis and/or conjunctivitis had all a typical history of
seasonal or perennial symptoms and positive SPT with pollen or
perennial allergens (house dust mites, animal dander from ALK,
Denmark). All asthmatic subjects had in addition a history of
wheezing and dyspnea during allergen exposure (American Thoracic
Society, 1995). Patients with food allergy showed a typical history of
food-induced allergy and had either a positive SPT or detectable
levels of food-specific serum IgE. Diagnosis in insect sting allergic
patients was based on clinical history, intracutaneous skin tests, and
specific IgE against bee or wasp venom in the serum (Pharmacia
ImmunoCAP System). The urticaria diagnosis was carried out on the
basis of clinical investigation and the typical history. Patients with
ACD had a clear clinical history of contact dermatitis after exposure
to a certain substance (such as nickel, cobaltchloride, and fragrance
mix) and a corresponding positive patch test with the relevant
substance, but no history or clinical signs of atopic dermatitis. Eleven
out of the 13 patients had active ACD at the time of testing. Affected
areas were in all cases areas other than the back tested and localized
mostly to face or hands. The 38 healthy controls without clinical
history of atopy were not sensitized to common allergens as
controlled by SPT and serologic screenings (fx5 and sx1) and had
a median total IgE of 50.6 kU/l (range 0.35–78). The study was
approved by the Ethical Committee of the University of Zurich and
was conducted according to the Declaration of Helsinki Principles.
All patients and controls gave written informed consent.
Allergens and allergen extracts
A crude M. sympodialis (ATCC; Strain No. 42132) extract was
prepared as described previously (Zargari et al., 1994). Recombinant
2418 Journal of Investigative Dermatology (2006), Volume 126
BF Casagrande et al.
Extrinsic and Intrinsic Atopic Eczema
M. sympodialis allergens rMala s 1 and rMala s 5–9 were produced
in Escherichia coli as described previously (Schmidt et al., 1997;
Lindborg et al., 1999; Rasool et al., 2000; Andersson et al., 2004).
Limulus amebocyte lysate test for purity was performed and
endotoxin doses (lipopolysaccharide) in all recombinant allergens
and the natural extract were well under the cutoff value (Pedersen
et al., 1994).
Determination of total and allergen-specific IgE
Specific serum IgE to M. sympodialis extract (ImmunoCAPm70) and
total serum IgE were determined for all patients and controls by the
ImmunoCAP system as prescribed by the manufacturer (Pharmacia
Diagnostics AB, Sweden). In the patient group with AE specific IgE to
common inhalant allergens (sx1, Pharmacia) and food allergens (fx5,
Pharmacia) were determined. IgE values X0.35 kU/l was defined
as atopic sensitization. In addition, an ELISA was established to
determine specific IgE to rMala s 1 and rMala s 5–9 as described
previously (Moser et al., 1994).
Skin tests
SPT was performed with M. sympodialis extract and with the
recombinant allergens rMala s 1 and rMala s 5–9. The proteins were
diluted in 0.9% sterile NaCl solution in a concentration of 100 mg/
ml. 0.9% NaCl and histamine hydrochloride 0.01% (ALK, Denmark)
served as negative and positive control, respectively. All skin tests
were performed in double on the volar forearm and applied in the
two opposite directions, using Stallerpointes devices (Trimedal,
Switzerland). The tests were evaluated after 15 minutes. Wheals and
flares were pen-marked and then transferred with scotch tape to a
paper. The mean wheal diameter was calculated by the addition of
the maximal longitudinal (d1) and transversal (d2) diameter divided
by two [(d1þ d2)/2]. A wheal diameter of X3 mm surrounded by
erythema was considered positive.
APT was performed under open conditions in 69 AE patients and
six healthy controls. No signs of eczema were allowed at the patch
test sites (on the back). The skin was tape-stripped 10 times with
scotch tape (2 cm, 3 M, Germany) as described previously (Darsow
et al., 1995; Langeveld-Wildschut et al., 1995). Thirty microliter
of each recombinant allergen (rMala s 1 and rMala s 5–9) at a
concentration of 100mg/ml were applied on paper discs in Finn
chambers (12 mm, Epitest Ltd, Hermal, Germany), in parallel with
30 ml M. sympodialis extract at a concentration of 5 mg/ml. NaCl
0.9% was used as a negative control. Oral corticosteroids were
discontinued for at least 6 weeks before testing. Topical cortico-
steroids, calcinneurin inhibitors, or UV therapy had not been used in
the last 3 weeks at test application sites. Reactions were read and
documented after 48 and 72 hours by a dermatologist. The APT was
considered as positive when there was at least an erythema and
infiltration (þ ) after 48 and/or 72 hours, according to the criteria of
conventional contact allergy patch testing (Wilkinson et al., 1970)
and corresponding at least with erythema and infiltration (a
oneþ reaction) considering the European Task force of atopic
dermatitis (EFTAD) guidelines for atopy patch testing (Darsow
et al., 2004).
Proliferative response of PBMC
In 16 AE patients (eight extrinsic and eight intrinsic) and three
healthy controls PBMCs were isolated from heparinized peripheral
venous blood by Ficoll density gradient centrifugation, washed three
times, and resuspended in Rosewell Park Memorial Institute media
1640 supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine,
50 mM 2-mercaptoethanol, 1% MEM non-essential amino acids and
vitamins, 100mg/ml streptomycin, 100 U/ml penicillin (all from
Life Technologies, Switzerland), and 10% heat-inactivated fetal calf
serum (Sera-Lab, UK). Samples of 5 105 cells/100 ml were stimu-
lated in round-bottomed 96-well plates with different concentra-
tions, ranging from 0.01 to 10 mg/ml of rMala s 1 and rMala s 5–9 or
M. sympodialis extract, respectively, in quadruplicates for 4 and 6
days. Phytohemagglutinin (10 mg/ml, Life Technologies, Switzerland)
was used as a positive control and BSA served as a negative control.
Proliferation was measured as incorporation of thymidine (DuPont-
NEN, Switzerland) during the final 8 hours of culture. The results
were expressed as mean c.p.m. for quadruplicates and as stimulation
index calculated as mean c.p.m. for stimulated cells divided by
mean c.p.m. for unstimulated cells. A stimulation index 42.5 was
considered as positive.
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